Intellia Therapeutics (NTLA) Research & Development (2015 - 2026)

Intellia Therapeutics (NTLA) has reported Research & Development for 12 consecutive years, with $80.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development fell 25.54% year-over-year to $80.7 million; the TTM figure through Mar 2026 stood at $361.2 million (down 21.97% YoY), while the FY2025 annual figure was $388.9 million, down 16.61% from the prior year.
• Research & Development eased to $80.7 million in Q1 2026 per NTLA's latest filing, from $88.7 million in the prior quarter.
• Across five years, Research & Development topped out at $133.1 million in Q1 2022 and bottomed at $80.7 million in Q1 2026.
• Historically, Research & Development has averaged $105.4 million across 5 years, with a median of $108.4 million in 2025.
• Annual changes were most pronounced in 2022 — Research & Development jumped 238.87% — and 2023, when it fell 27.03%.
• Intellia Therapeutics' Research & Development stood at $100.0 million in 2022, then advanced by 8.94% to $109.0 million in 2023, then gained by 7.25% to $116.9 million in 2024, then fell by 24.15% to $88.7 million in 2025, then decreased by 8.93% to $80.7 million in 2026.
• Business Quant data shows NTLA's Research & Development at $80.7 million in Q1 2026, $88.7 million in Q4 2025, and $94.7 million in Q3 2025.